This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| John D. Sampson | |
|---|---|
| Name | John D. Sampson |
| Birth date | 1970s |
| Nationality | American |
| Fields | Oncology, Cancer Genetics, Translational Medicine |
| Workplaces | Duke University, Duke Cancer Institute |
| Alma mater | Dartmouth College, Duke University School of Medicine |
| Known for | Discovery of RHOA mutations in gastric cancer, work on genomic drivers of cancer |
| Awards | American Association for Cancer Research honors |
John D. Sampson
John D. Sampson is an American physician-scientist and oncology researcher noted for translational work in cancer genomics, tumor microenvironment, and targeted therapeutics. He has held faculty appointments at prominent academic medical centers and led multidisciplinary teams integrating molecular pathology, bioinformatics, and clinical oncology to advance precision medicine. His career bridges clinical practice in surgical oncology, laboratory investigation into cancer drivers, and institutional leadership in cancer centers and research consortia.
Sampson earned undergraduate and medical degrees with training that connected liberal arts and biomedical science; he completed undergraduate studies at Dartmouth College and medical training at Duke University School of Medicine. During postgraduate clinical training he undertook residencies and fellowships that involved institutions such as Duke University Hospital and specialty programs affiliated with surgical oncology centers. His formative mentors and collaborators included faculty from departments associated with National Cancer Institute–funded programs, translational research initiatives, and interdisciplinary cancer centers. Sampson's early exposure to laboratory research involved collaborations with investigators working on molecular profiling platforms, next-generation sequencing consortia, and pathology core facilities at major academic centers like Johns Hopkins Hospital and Memorial Sloan Kettering Cancer Center through visiting scholar exchanges and conference networks such as the American Association for Cancer Research.
Sampson built a career combining clinical surgical oncology practice with laboratory-based cancer genetics and translational science at institutions including the Duke Cancer Institute. He has directed research programs that partnered with consortia such as the The Cancer Genome Atlas and engaged with technology platforms from companies and cores associated with Illumina, Thermo Fisher Scientific, and academic bioinformatics groups. His laboratory employed methods developed in collaboration with groups from Broad Institute and utilized analytical tools referenced in publications from Nature, Science, and The New England Journal of Medicine. Sampson served on grant panels for organizations such as the National Institutes of Health and participated in peer-review for journals tied to the American Association for Cancer Research and the American Society of Clinical Oncology. His translational efforts frequently intersected with clinical trial networks including NCI Community Oncology Research Program sites and cooperative groups like the Alliance for Clinical Trials in Oncology.
Sampson's research contributions include identification and characterization of genomic alterations implicated in gastrointestinal and central nervous system tumors, with work cited alongside teams reporting mutations in genes such as RHOA, TP53, and pathways involving PI3K signaling. His group contributed to molecular taxonomy efforts that paralleled classifications published by The Cancer Genome Atlas and investigators at Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center. He advanced methodologies for integrating histopathology from cores like Molecular Pathology laboratories with sequencing outputs used in precision oncology pipelines developed at centers such as Dana–Farber Cancer Institute. Sampson's translational work informed biomarker-driven clinical trials that involved targeted agents engineered by biotechnology firms collaborating with academic centers, mirroring trials organized by networks like European Society for Medical Oncology and ASCO. Publications from his lab addressed tumor heterogeneity, stromal interactions studied in models referenced by groups at Cold Spring Harbor Laboratory, and therapeutic resistance mechanisms described in literature from Cell and Nature Medicine.
Sampson has received recognitions from professional organizations and internal institutional awards consistent with leadership in translational oncology. His honors include acknowledgments from bodies such as the American Association for Cancer Research and institutional investigator awards from academic medical centers similar to Duke University School of Medicine. He has been invited to present plenary and keynote lectures at conferences organized by Society for Immunotherapy of Cancer, the American Society of Clinical Oncology, and international symposia hosted by associations like the International Cancer Research Partnership.
Sampson has been associated with legal and institutional controversy involving allegations of research misconduct and clinical oversight that prompted investigations by university compliance offices and external regulatory entities. The matters drew attention from media outlets covering higher education and biomedical research, and involved actions by institutional review committees and legal counsel. Proceedings engaged stakeholders including hospital administrators, academic review panels, and, at times, state-level regulatory authorities. Outcomes included administrative reviews, litigation filed in civil courts, and settlements or adjudications that were reported in press and public records related to academic integrity and clinical accountability at medical institutions.
Outside of academic duties, Sampson has participated in outreach and philanthropic activities linked to cancer patient advocacy groups and institutional fundraising efforts aligned with centers such as the Duke Cancer Institute and community-based organizations. He has collaborated with nonprofit groups that support cancer research and patient services, analogous to partnerships seen between academic investigators and organizations like the American Cancer Society and regional foundations. Sampson's personal interests reportedly include engagement with professional societies, mentoring programs for trainees affiliated with universities and research consortia, and involvement in community health initiatives connected to major hospital systems.
Category:American oncologists Category:Cancer researchers